💡 Introduction to Vaccination & Immunisation
Vaccination is the process of administering a vaccine — a biological preparation — that stimulates the body's immune system to produce immunity against a specific disease without causing the actual disease. Immunisation is the broader process by which an individual becomes protected against an infectious disease, either through vaccination (active) or antibody transfer (passive).
💉
Lives Saved/Year
2–3 Million
By vaccines globally (WHO)
🌍
Eradicated
Smallpox (1980)
First disease eradicated by vaccine
🇮🇳
India UIP Launched
1978
Universal Immunisation Programme
👶
Target Group
0–2 Years
Primary UIP target children
🏥
Herd Immunity
70–95%
Coverage needed (varies by disease)
🏆
Near Eradicated
Polio
Wild polio virus near elimination
🛡️ Types of Immunity – Foundation
| Type | Sub-type | Mechanism | Example | Duration |
| Active Immunity | Natural Active | Body produces antibodies after surviving an infection | Recovering from measles → lifelong immunity | Long-lasting / Lifelong |
| Artificial Active | Body produces antibodies after receiving a vaccine | Receiving MMR vaccine | Long-lasting (may need boosters) |
| Passive Immunity | Natural Passive | Antibodies transferred from mother to baby | IgG crosses placenta; IgA in breast milk (colostrum) | Temporary (3–6 months) |
| Artificial Passive | Ready-made antibodies given externally | Anti-tetanus serum (ATS), Anti-rabies serum, HBIG | Very short-lived (weeks) |
🧠
Mnemonic – Types of Immunity: "NANA PAIR"
NAtural Active = Natural infection → your own antibodies
NAtural Passive = Mother → Baby (placenta/colostrum)
PAssive Artificial = Ready-made antibodies injected (ATS, HBIG)
IRtificial Active = Vaccine stimulates your own antibody production
👉 Active immunity = YOU make the antibodies (slow onset, long duration). Passive immunity = BORROWED antibodies (immediate onset, short duration)
👥 Herd Immunity (Community Immunity)
Herd immunity occurs when a sufficiently large proportion of a community becomes immune to an infection (through vaccination or prior infection), thereby reducing the likelihood of further spread — even protecting those who are not immune (immunocompromised, too young to vaccinate, etc.).
| Disease | Herd Immunity Threshold | Vaccine |
| Measles | 92–95% (highest — very contagious R₀ = 12–18) | MMR / MR / Measles vaccine |
| Polio | 80–85% | OPV / IPV |
| Smallpox | 80–85% | Vaccinia (achieved eradication) |
| Diphtheria | 83–85% | DPT / DT / Td |
| COVID-19 | ~70% (estimated) | mRNA, Adenoviral vector |
🟢
Live Attenuated Vaccines
Weakened (attenuated) live organism — strongest immune response — closest to natural infection
Live attenuated vaccines contain weakened (attenuated) but living microorganisms that can replicate in the host but do NOT cause disease in immunocompetent individuals. They produce a strong, long-lasting immune response similar to natural infection — stimulating both humoral (antibody) AND cellular immunity.
🧠
Mnemonic – Live Attenuated Vaccines: "BCG & MMR – BOYS Always Vow Zealously"
BCG (Tuberculosis)
OPV – Oral Polio Vaccine (Sabin)
Yellow Fever vaccine
Measles vaccine / MMR
Mumps vaccine
Rubella vaccine
Varicella (Chickenpox) vaccine
Zoster (Herpes Zoster/Shingles) vaccine
Rotavirus vaccine (oral)
Influenza (LAIV – intranasal)
Typhoid (oral Ty21a)
Easy remember: "BCG MMR VZR OT" → BCG, MMR, Varicella, Zoster, Rotavirus, OPV, Typhoid (oral)
🟢
Live Attenuated – Key Properties
Strongest immune response
Weakened live organism
| Organism | Live but weakened (attenuated) — cannot cause disease |
| Replication | YES — replicates in host (like natural infection) |
| Immunity Type | Both humoral (B cells/antibodies) AND cellular (T cells) |
| Doses needed | Usually 1 dose sufficient (powerful response) |
| Adjuvant needed? | No — replication itself provides adequate stimulation |
| Duration | Long-lasting / lifelong (often) |
| Stability | Heat sensitive — requires cold chain strictly |
| Storage | 2–8°C (some require freezing: OPV at −20°C) |
🟢 ADVANTAGE: Best immune response. DISADVANTAGE: Risk of reversion to virulence (rare) — risk in immunocompromised patients. CONTRAINDICATED in pregnancy & immunocompromised!
🚨
Critical Contraindications for ALL Live Vaccines: (1) Pregnancy — risk of fetal infection. (2) Immunocompromised patients (HIV, on immunosuppressants, chemotherapy, steroids >2 weeks, congenital immunodeficiency). (3) Severe febrile illness (defer until recovered). Exception: BCG is given even in HIV-exposed infants unless symptomatic HIV.
BCG Vaccine
Bacillus Calmette-Guérin (TB vaccine)
Live Attenuated | Intradermal
| Protects against | Tuberculosis (miliary TB, TB meningitis in children) |
| Type | Live attenuated Mycobacterium bovis |
| Route | Intradermal (ID) — LEFT upper arm (deltoid region) |
| Dose | 0.05 mL (birth) | 0.1 mL (after 1 month) |
| When given | At BIRTH (as early as possible, within first week) |
| Storage | 2–8°C (NOT frozen) |
| Reaction | Indurated nodule → ulceration → scar (normal reaction, takes 6–12 weeks) |
| Scar significance | Scar = evidence of successful vaccination |
| Test association | Mantoux test (PPD) turns positive after BCG — use IGRA for diagnosis |
OPV (Sabin Vaccine)
Oral Polio Vaccine
Live Attenuated | Oral drops
| Protects against | Poliomyelitis (all 3 serotypes) |
| Type | Live attenuated poliovirus (Sabin) |
| Route | Oral — 2 drops in mouth |
| Doses | Birth + 6, 10, 14 weeks + boosters |
| Storage | −20°C (freezer) — MOST FREEZE-SENSITIVE |
| Advantage | Intestinal immunity (IgA), herd immunity, easy to administer |
| Disadvantage | VAPP (Vaccine-Associated Paralytic Polio) — 1 in 2.7 million doses |
| IPV | Inactivated Polio Vaccine (killed) — given IM, no VAPP risk, added to UIP |
MMR Vaccine
Measles-Mumps-Rubella
Live Attenuated | Subcutaneous
| Protects against | Measles, Mumps, Rubella (German Measles) |
| Type | Live attenuated (all 3 components) |
| Route | Subcutaneous (SC) — upper arm |
| Schedule (India) | MR vaccine at 9 months & 16–24 months (India UIP); MMR in private practice |
| Storage | 2–8°C (protected from light) |
| Contraindication | Pregnancy (teratogenic), immunocompromised, egg allergy (severe) |
| Rubella importance | Prevents Congenital Rubella Syndrome (CRS) in babies |
| Note | No proven link to autism (multiple large studies confirmed safety) |
Rotavirus Vaccine
Rotarix / RotaTeq / ROTAVAC
Live Attenuated | Oral
| Protects against | Severe rotavirus gastroenteritis (diarrhoea) — leading childhood killer |
| Type | Live attenuated oral vaccine |
| Route | Oral drops |
| Schedule | 6, 10, 14 weeks (India UIP — ROTAVAC 116E) |
| Contraindication | Severe immunodeficiency; history of intussusception |
| India vaccine | ROTAVAC (indigenously developed by Bharat Biotech) — introduced in UIP 2016 |
| Efficacy | ~53% against severe rotavirus diarrhoea in India |
Yellow Fever Vaccine
17D strain vaccine
Live Attenuated | Subcutaneous
| Protects against | Yellow Fever (Flavivirus) |
| Type | Live attenuated 17D strain of yellow fever virus |
| Route | Subcutaneous (SC) |
| Single dose | One dose = lifelong protection (WHO revised from 10-yearly booster) |
| Certificate | International Certificate of Vaccination (ICV) required for travel to endemic areas |
| Valid from | 10 days after vaccination (previously 10 years but now LIFELONG per WHO) |
| Contraindication | Infants <6 months, pregnancy, immunocompromised, severe egg allergy, thymus disease |
Varicella & Zoster Vaccines
Chickenpox & Shingles vaccines
Live Attenuated | Subcutaneous
| Varicella vaccine | Prevents chickenpox (VZV) — 2 doses (12–15 months, 4–6 years) |
| Zoster vaccine (Zostavax) | Live — prevents shingles reactivation in adults >50 years |
| Shingrix | Recombinant (non-live) zoster vaccine — preferred over Zostavax (more effective) |
| Route | Subcutaneous (SC) |
| Contraindication | Pregnancy, severe immunosuppression, neomycin allergy |
🔵
Killed / Inactivated Vaccines
Dead microorganism — safer but weaker immune response — multiple doses needed — adjuvants used
Killed/inactivated vaccines contain whole microorganisms that have been killed (inactivated) by heat, chemical (formaldehyde), or radiation. They CANNOT replicate in the host → weaker immune response → require multiple doses and adjuvants to achieve adequate immunity. SAFER — no risk of disease from vaccine.
🧠
Mnemonic – Killed/Inactivated Vaccines: "PIT RICH"
Pertusis (whole cell — in DPT)
IPV – Inactivated Polio Vaccine (Salk)
Typhoid (TAB vaccine, Vi polysaccharide IM)
Rabies vaccine (HDCV, PCECV)
Influenza (whole virion killed)
Cholera vaccine (killed whole cell)
Hepatitis A vaccine (killed HAV)
Also: Plague vaccine, Japanese Encephalitis (killed), Q-fever vaccine
🔵
Killed Vaccines – Key Properties
Inactivated organisms
Dead microorganism
| Organism | Dead (killed by heat, chemicals, radiation) |
| Replication | NO — cannot replicate in host |
| Immunity Type | Mainly humoral (antibody-mediated) — weaker cellular immunity |
| Doses needed | Multiple doses required (primary + boosters) |
| Adjuvant needed? | YES — needed to enhance immune response (aluminium salts) |
| Duration | Shorter — requires boosters |
| Safety | Safer — no risk of reversion to virulence |
| Storage | 2–8°C (should NOT be frozen — freezing damages killed vaccines) |
🔵 ADVANTAGE: Safe in immunocompromised & pregnancy (most). DISADVANTAGE: Weaker, shorter immunity. Multiple doses + boosters needed. Adjuvant required. Freeze damage risk!
⚠️
Freeze-Sensitive Vaccines (MUST NOT BE FROZEN): DPT, DT, TT, Hepatitis B, Hib, Pentavalent, IPV, Typhoid Vi, Rabies, Meningococcal, Pneumococcal. Freezing causes loss of potency — use Freeze Indicator Cards (FIC) / Shake Test to detect freeze damage. These are stored at 2–8°C ONLY.
IPV (Salk Vaccine)
Inactivated Polio Vaccine
Killed | IM injection
| Type | Formalin-inactivated poliovirus (all 3 types) |
| Route | Intramuscular (IM) or Subcutaneous |
| Advantage | No VAPP risk; safe in immunocompromised |
| Disadvantage | No intestinal (mucosal) immunity unlike OPV; expensive; requires injection |
| UIP India | IPV added to Indian UIP — given fractional dose (0.1 mL ID) at 6 & 14 weeks |
| Storage | 2–8°C — freeze sensitive |
Hepatitis A Vaccine
HAV (Killed)
Killed | IM injection
| Type | Formalin-inactivated Hepatitis A virus |
| Route | Intramuscular (IM) |
| Schedule | 2 doses: primary + booster 6–12 months later |
| Safe in | Immunocompromised, pregnancy (no live virus) |
| Indication | Travellers to endemic areas, food handlers, children in endemic regions |
| Storage | 2–8°C — freeze sensitive |
Rabies Vaccine
HDCV / PCECV / PVRV
Killed | IM injection
| Types | HDCV (Human Diploid Cell Vaccine), PCECV, PVRV (Vero cell) |
| Route | Intramuscular (IM) — deltoid (NOT gluteal — poor response) |
| Pre-exposure | Days 0, 7, 21/28 (3 doses) |
| Post-exposure | Days 0, 3, 7, 14 (Essen regimen) — 4 doses with RIG on Day 0 |
| RIG (Rabies Immunoglobulin) | HRIG or ERIG — given on Day 0 with first dose, infiltrated around wound |
| Wound care | Thorough washing with soap and water for 15 minutes = FIRST action after animal bite |
Influenza Vaccine
Flu vaccine (killed)
Killed (TIV/QIV) | IM
| Types | TIV (Trivalent) or QIV (Quadrivalent) — killed whole virus |
| Route | Intramuscular (IM); LAIV (live) = intranasal spray |
| Frequency | ANNUAL vaccination — virus mutates (antigenic drift) |
| Recommended for | Elderly (>65), healthcare workers, chronic disease patients, pregnant women, children 6m–5yrs |
| Contraindication | Severe egg allergy (contains egg proteins); LAIV contraindicated in immunocompromised |
Cholera Vaccine
Oral / Parenteral
Killed whole cell
| Types | Oral (WC/rBS) — preferred. Parenteral (heat-killed — old, less used) |
| Efficacy | ~50–60% for 3–5 years (oral vaccine) |
| Indication | Travellers to endemic areas; outbreak control; endemic populations |
| Key fact | NOT included in routine UIP India; used in outbreak settings |
Typhoid Vaccines
TAB / Vi polysaccharide / Ty21a (oral)
Killed + Subunit + Live
| TAB Vaccine | Killed (Heat/phenol inactivated S. Typhi + S. Paratyphi) — old, not recommended now |
| Vi Polysaccharide | Subunit — capsular polysaccharide; IM; 1 dose; 2 years duration; NOT <2 years |
| Ty21a (Oral) | Live attenuated; oral capsules; 3–4 doses every other day; NOT <6 years; 5 years protection |
| Vi Conjugate | Newer; effective from 6 months; used in TCV (Typhoid Conjugate Vaccine) in India's UIP |
| India UIP | TCV (Typhoid Conjugate Vaccine) introduced — for infants from 9 months |
🔴
Toxoid Vaccines
Inactivated bacterial TOXIN — immunity against the toxin, not the organism itself
Toxoid vaccines are prepared from bacterial exotoxins that have been chemically inactivated (usually with formaldehyde) to remove toxicity while retaining their immunogenicity (ability to stimulate immune response). The immune system makes antibodies against the toxin (antitoxin) — not against the bacteria itself. These are very stable and safe vaccines.
🧠
Mnemonic – Toxoid Vaccines: "DT & TT — Double TroublE makes Toxoid Two"
Diphtheria Toxoid (component of DPT, DT, Td)
Tetanus Toxoid (TT, Td, DPT) — MOST IMPORTANT
👉 Only Diphtheria and Tetanus are currently covered by toxoid vaccines. Clostridium perfringens and Botulinum toxoids also exist but not in routine UIP.
Adjuvant used: Alum (Aluminium Hydroxide) — adsorbs toxoid, prolongs immune stimulation = "Adsorbed" vaccines (APT, ADSORBATE)
🔴
Toxoid Vaccines – Key Properties
Inactivated bacterial toxin
Modified toxin (inactivated)
| Preparation | Toxin treated with formaldehyde → toxoid (no toxicity, retains antigenicity) |
| Immunity | Antitoxin antibodies — NOT against the bacteria itself |
| Organism killed? | N/A — no organism — just the toxin (modified) |
| Adjuvant | Aluminium hydroxide (alum) — enhances immune response |
| Safety | Extremely safe — no living or dead organism |
| Doses | Multiple doses + boosters (primary series + maintenance) |
| Storage | 2–8°C — freeze sensitive (aluminium salt damaged by freezing) |
🔴 Toxoid = "Anatoxin" in French. Formaldehyde treatment inactivates toxicity but preserves immunogenicity. Alum adjuvant = "depot effect" — slow release = prolonged immune stimulation.
Tetanus Toxoid (TT)
Tetanus Toxoid Vaccine
Toxoid | IM injection
| Protects against | Tetanus (Clostridium tetani toxin) |
| Preparation | Tetanospasmin toxin + formaldehyde = Tetanus Toxoid |
| Route | Intramuscular (IM) — deltoid or anterolateral thigh |
| Pregnancy TT schedule | TT1: Early pregnancy (1st contact) | TT2: 4 weeks after TT1 | Booster: if previous TT within 3 years |
| Primary immunisation | 3 doses (as DPT at 6, 10, 14 weeks) + boosters at 16–24 months, 5 years, 10 years, 16 years |
| Neonatal tetanus prevention | 2 doses TT to mother >4 weeks apart → infant protected at birth |
| Post-exposure | Clean wound + immunised: no action. Tetanus-prone wound + unimmunised: TT + TIG (Tetanus Immune Globulin) |
| TIG (Tetanus Immunoglobulin) | Passive immunity — 500 IU IM; given with TT (different sites) for contaminated wounds in unimmunised |
DPT Vaccine
Diphtheria-Pertussis-Tetanus
Combined: Toxoid + Killed | IM
| Components | D = Diphtheria Toxoid | P = Killed Bordetella pertussis (whole cell) | T = Tetanus Toxoid |
| Type | D & T = Toxoid | P = Killed organism (whole cell) |
| Route | Intramuscular (IM) — anterolateral thigh (<2 yrs) or deltoid (>2 yrs) |
| Schedule | Primary: 6, 10, 14 weeks | Booster 1: 16–24 months | Booster 2: 5 years |
| Upper age limit | DPT not given after age 7 (use Td — adult formulation with low D) |
| Side effects | Fever, local pain/swelling (from P component), rarely high-pitched cry, febrile seizure, HHE |
| Acellular pertussis (DTaP) | Purified pertussis proteins — fewer side effects; used in developed countries |
| Storage | 2–8°C — NEVER freeze (freeze destroys it) |
Pentavalent Vaccine
DPT + Hep B + Hib (5-in-1)
Combination Vaccine | IM
| Components | DPT (Diphtheria + Pertussis + Tetanus) + Hepatitis B + Hib (Haemophilus influenzae type b) |
| Schedule | 6, 10, 14 weeks (India UIP) — replaced separate DPT + Hep B |
| Route | Intramuscular (IM) — anterolateral thigh |
| Introduced in India | 2011 (phased introduction in UIP) |
| Advantages | Fewer injections, reduces vaccine fatigue, same immunogenicity |
| Storage | 2–8°C — freeze sensitive |
Td / dT Vaccine
Adult Tetanus-Diphtheria (low-dose D)
Toxoid | Adults & Boosters
| Use | Booster for adults/adolescents >7 years; pregnancy TT booster |
| Difference from DT | Low-dose diphtheria (d) — reduces local reactions in older patients |
| Schedule | Every 10 years for tetanus boosters in adults; Tdap once (includes acellular pertussis) |
| Pregnancy | Td/TT given in pregnancy to prevent maternal and neonatal tetanus |
🟣
Subunit, Conjugate, Recombinant & mRNA Vaccines
Modern vaccine technology — use parts of the pathogen or genetic instructions
🧠
Mnemonic – Subunit/Recombinant Vaccines: "HiPP HMR"
Hepatitis B (recombinant)
iHPV – Human Papillomavirus (VLP)
Pneumococcal (PCV – conjugate)
Pertussis acellular (DTaP – subunit)
Hib conjugate
Meningococcal (conjugate)
Recombinant Zoster vaccine (Shingrix)
🧬
Hepatitis B Vaccine
Recombinant DNA vaccine
Recombinant Subunit – HBsAg
| Type | Recombinant HBsAg (Surface Antigen) produced in yeast (Saccharomyces cerevisiae) |
| Route | Intramuscular (IM) — deltoid (adults); anterolateral thigh (infants) |
| Schedule (UIP) | Birth (within 24 hours) + 6, 10, 14 weeks (as Pentavalent) |
| Birth dose | Single component Hep B within 24 hours of birth — prevents vertical transmission |
| Response check | Anti-HBs titre after 3 doses — >10 mIU/mL = protective |
| Non-responders | Repeat 3-dose series; if still no response = permanent non-responder (rare) |
| Storage | 2–8°C — NEVER freeze |
🧬 Hep B birth dose within 24 hours prevents 70–95% of mother-to-child transmission! HBIG (Hepatitis B Immunoglobulin) given WITH Hep B vaccine to HBsAg-positive mother's infant for passive + active protection.
🌸
HPV Vaccine
Virus-Like Particles (VLP)
Recombinant VLP – Cervical Cancer Prevention
| Type | Virus-Like Particles (VLP) — recombinant capsid proteins; NO viral DNA |
| Vaccines | Cervarix (bivalent: HPV 16,18), Gardasil (quadrivalent: 6,11,16,18), Gardasil 9 (9-valent) |
| Route | Intramuscular (IM) |
| Target age | Girls 9–14 years (before sexual debut — optimal); India UIP: Class 6 girls (9–14 yrs) |
| Schedule (<15 yrs) | 2 doses: 0 and 6 months |
| Schedule (≥15 yrs or immunocompromised) | 3 doses: 0, 1–2, 6 months |
| India UIP | Cervavac (indigenously developed quadrivalent HPV vaccine) added to UIP 2023 for girls 9–14 yrs |
🌸 HPV 16 & 18 = cause 70% of cervical cancers. HPV 6 & 11 = cause genital warts. Best given BEFORE sexual debut — does NOT treat existing HPV infection. CERVAVAC = India's indigenous HPV vaccine!
🫁
Pneumococcal Vaccines
PCV (Conjugate) & PPSV (Polysaccharide)
Conjugate / Polysaccharide
| PCV (Pneumococcal Conjugate) | PCV10, PCV13, PCV15, PCV20 — conjugated to carrier protein → T-cell dependent — effective in infants |
| PPSV23 | 23-valent polysaccharide — T-cell INDEPENDENT — NOT effective <2 years; adults & elderly |
| India UIP | PCV introduced in UIP (select states) — 6, 14 weeks + booster at 9 months |
| Target | Children <5 yrs, Elderly >65, Immunocompromised (PCV preferred) |
| Route | Intramuscular (IM) |
🫁 Conjugate vaccines (PCV) = polysaccharide LINKED to protein carrier → converts T-cell independent response to T-cell dependent → effective in infants under 2 years!
🧬
mRNA Vaccines
COVID-19 vaccines – Modern technology
mRNA technology – NEW generation
| Examples | Pfizer-BioNTech (Comirnaty), Moderna (Spikevax) — COVID-19 |
| Mechanism | mRNA encodes for spike protein of virus → body's cells produce spike protein → immune response |
| Does NOT | Does NOT enter cell nucleus; does NOT alter DNA; mRNA degraded after few days |
| Advantages | Rapid development, can be modified quickly for variants, highly effective |
| Storage | Ultra-cold (-70°C for Pfizer original; -20°C for Moderna); newer formulations need only 2–8°C |
| India COVID vaccines | Covishield (ChAdOx1 — adenoviral vector), Covaxin (killed whole virion — BBV152), mRNA coming |
🧬 mRNA vaccines represent a REVOLUTION in vaccinology. Covaxin (India's indigenous killed vaccine by Bharat Biotech) was the world's first whole-virion inactivated COVID-19 vaccine approved.
📊 Vaccine Types – Master Comparison Table
🚨
MOST HIGH-YIELD for NORCET! Know whether each vaccine is live, killed, or toxoid — and its key properties. This comparison is tested in almost every nursing exam.
| Property | 🟢 Live Attenuated | 🔵 Killed/Inactivated | 🔴 Toxoid |
| Content | Weakened live organism | Dead organism (killed) | Inactivated toxin (formaldehyde) |
| Replication in host | Yes | No | No organism — toxin only |
| Immune response | Strongest — humoral + cellular | Mainly humoral | Antitoxin antibodies |
| Doses needed | Usually 1 | Multiple (2–4+) | Multiple + boosters |
| Adjuvant needed | No | Yes (alum) | Yes (alum) |
| Duration of immunity | Long / Lifelong | Shorter — needs boosters | Shorter — needs boosters |
| Risk of disease | Very rare (reversion) — VAPP in OPV | No risk | No risk |
| Safe in immunocompromised? | ⚠️ NO (avoid) | ✅ YES | ✅ YES |
| Safe in pregnancy? | ⚠️ Generally NO | ✅ Most yes (IPV, Hep A, flu) | ✅ YES (TT mandatory in pregnancy) |
| Storage / Stability | Heat sensitive — strict cold chain | Freeze sensitive — 2–8°C only | Freeze sensitive — 2–8°C only |
| Examples | BCG, OPV, MMR, Varicella, Yellow Fever, Rotavirus, Influenza (LAIV) | IPV, DPT (P component), Hep A, Rabies, Influenza (killed), Typhoid (Vi), Cholera | Tetanus Toxoid, Diphtheria Toxoid (DT, DPT-D, Td) |
🗓️
Universal Immunisation Programme (UIP) – India
National schedule — all vaccines, ages, routes, doses at a glance
The Universal Immunisation Programme (UIP) was launched in India in 1978 (initially as EPI — Expanded Programme on Immunisation, then UIP from 1985). India's UIP is one of the LARGEST immunisation programmes in the world, covering 12 vaccine-preventable diseases with newer additions ongoing.
🧠
Mnemonic – UIP India Diseases Covered: "PPDD MMT HCHH"
Polio
Pertusis (Whooping cough)
Diphtheria
Diarrhoea (Rotavirus)
Measles / Rubella (MR)
Meningitis (Hib — via Pentavalent)
Tetanus (Neonatal + Maternal)
Hepatitis B
Cervical Cancer (HPV — Cervavac)
Hib (Pneumonia/Meningitis)
Human Papillomavirus
Typhoid (TCV)
| Age | Vaccine | Route | Site | Dose |
| Birth |
BCG + OPV 0 + Hepatitis B (birth dose) |
ID + Oral + IM |
Left upper arm + Mouth + Anterolateral thigh |
0.05 mL + 2 drops + 0.5 mL |
| 6 Weeks |
OPV 1 + Pentavalent 1 + Rotavirus 1 + IPV 1 (fIPV — fractional) |
Oral + IM + Oral + ID |
Mouth + Thigh + Mouth + Right upper arm |
Standard doses |
| 10 Weeks |
OPV 2 + Pentavalent 2 + Rotavirus 2 |
Oral + IM + Oral |
Mouth + Thigh + Mouth |
Standard doses |
| 14 Weeks |
OPV 3 + Pentavalent 3 + Rotavirus 3 + IPV 2 (fIPV) |
Oral + IM + Oral + ID |
Mouth + Thigh + Mouth + Right upper arm |
Standard doses |
| 9 Months |
MR 1 + Vitamin A 1 (1 lakh IU) + PCV Booster |
SC + Oral + IM |
Right upper arm + Mouth + Thigh |
0.5 mL + 1 mL + 0.5 mL |
| 9–12 Months |
Typhoid Conjugate Vaccine (TCV) |
IM |
Anterolateral thigh |
0.5 mL |
| 16–24 Months |
MR 2 + OPV Booster + DPT Booster 1 + Vitamin A 2 (2 lakh IU) |
SC + Oral + IM + Oral |
Right arm + Mouth + Left thigh + Mouth |
0.5 mL each |
| 5 Years |
DPT Booster 2 + OPV Booster |
IM + Oral |
Left upper arm + Mouth |
0.5 mL + 2 drops |
| 9–14 Years (Girls) |
HPV (Cervavac) — 2 doses (0 and 6 months) |
IM |
Upper arm |
0.5 mL |
| 10 & 16 Years |
TT (Tetanus Toxoid) |
IM |
Upper arm |
0.5 mL |
| Pregnancy |
TT1 (early) + TT2 (4 wks after TT1) / Booster if <3 yrs since last TT |
IM |
Upper arm |
0.5 mL each |
❄️
Cold Chain in Immunisation
System to maintain vaccine potency from manufacturer to patient — temperature critical
The Cold Chain is a system of storing and transporting vaccines at recommended temperatures (between +2°C and +8°C for most vaccines, −20°C for OPV) from the point of manufacture to the point of administration. Breaking the cold chain renders vaccines ineffective.
🥶
−20°C
Deep Freezer (DF)
OPV (Oral Polio Vaccine) stored here. Regional vaccine store level. Also used for ice pack conditioning.
🧊
+2 to +8°C
ILR (Ice-Lined Refrigerator)
Most vaccines stored here at PHC/CHC level. Maintains temperature even during power cuts (12–24 hrs). BCG, MMR, DPT, Hep B, Pentavalent.
📦
+2 to +8°C
Cold Box / Vaccine Carrier
Used for transporting vaccines from PHC to outreach/session sites. Maintains temperature for 12–24 hrs with ice packs.
🔷
Frozen solid
Ice Packs / Cold Packs
Filled with water, frozen at −20°C. Used in vaccine carriers and cold boxes. Conditioned before use (to prevent freeze damage to freeze-sensitive vaccines).
🌡️ Vaccine Vial Monitors (VVM) & Cold Chain Indicators
| Indicator | Purpose | How It Works | Action |
| VVM (Vaccine Vial Monitor) | Detect heat exposure (cumulative heat damage) | Square inside circle on vial label. If inner square is LIGHTER than outer circle = OK. If DARKER or SAME = discard | VVM dark = DISCARD vaccine |
| FIC (Freeze Indicator Card) | Detect freezing of freeze-sensitive vaccines | Changes colour if vaccine has been frozen; cannot be reversed | FIC triggered = SHAKE TEST → if clumps remain = discard |
| Shake Test | Detect freeze damage in adsorbed vaccines (DPT, DT, TT, Hep B) | Shake suspect vial and control vial, set aside 30 min — if flocculates settle in suspect (vs milky in control) = freeze-damaged | Positive shake test = DISCARD |
| Cold Chain Thermometer | Monitor refrigerator temperature twice daily | Record morning and afternoon temperatures in vaccine temperature log | Out of range = report immediately |
🧠
Cold Chain Rule: "OPV FREEZES — Others 2 to 8"
OPV = Store at −20°C (freeze)
BCG = 2–8°C (can tolerate mild freezing)
MMR / Varicella = 2–8°C (light sensitive)
DPT / DT / TT / Hep B / Pentavalent / IPV = 2–8°C only (NEVER freeze)
👉 FREEZE-SENSITIVE vaccines (DPT, DT, TT, Hep B, Pentavalent, IPV, Typhoid Vi) must NEVER be frozen — aluminium salt (alum) adjuvant clumps irreversibly!
⚠️ AEFI – Adverse Events Following Immunisation
AEFI (Adverse Event Following Immunisation) is any untoward medical occurrence which follows immunisation and does not necessarily have a causal relationship with the vaccine. Classification: vaccine-related, programme-related, coincidental, or unknown.
| AEFI Type | Description | Examples | Management |
| Minor (Local reactions) | Most common; expected; self-limiting | Pain, redness, swelling at injection site; mild fever; irritability | Paracetamol for fever; cold compress; reassure parents |
| BCG Reactions | Normal localised reaction | Induration → ulceration → scar (normal). BCG abscess if deep injection. Keloid in susceptible | Normal scar = no action. Abscess = cold compress; refer if large |
| Febrile Seizure | Due to fever, usually 6–12 hrs after DPT | Convulsion with fever after DPT/MMR | Antipyretic premedication; manage seizure; usually benign; acellular DTaP for future |
| Anaphylaxis | Severe immediate hypersensitivity — rare but serious | Within 15–30 min: urticaria, bronchospasm, hypotension, collapse | Adrenaline (Epinephrine) 0.01 mg/kg IM thigh = FIRST action; O₂; IV fluids; observe 30 min post-vaccination |
| VAPP | Vaccine-Associated Paralytic Polio from OPV | Rare (1 in 2.7 million doses); paralysis similar to wild polio | IPV now added to UIP to reduce risk; supportive care; report |
| HHE | Hypotonic Hyporesponsive Episode — DPT related | Baby goes limp, pale, unresponsive for minutes after DPT; recovers fully | Usually self-limiting; reassure parents; acellular pertussis for next dose |
| Persistent Crying | >3 hours high-pitched cry after DPT — P component | Inconsolable high-pitched cry for >3 hours within 48 hrs of DPT | Usually benign; paracetamol; substitute acellular pertussis |
| Programme Error | Wrong dose, wrong route, wrong site, wrong vaccine | BCG given SC instead of ID; overdose; contaminated vaccine | Report; manage specific complication; prevent recurrence |
🚨
ANAPHYLAXIS after vaccination — First Action: Epinephrine (Adrenaline) 1:1000 → 0.01 mg/kg IM into outer thigh. ALWAYS observe patients for 30 minutes after vaccination at the facility before allowing them to leave. Keep emergency kit (adrenaline, antihistamine, IV fluids) at every vaccination site!
🚫 Vaccine Contraindications
| Vaccine | True Contraindication | False Contraindication (Common Myths) |
| ALL Vaccines | Anaphylaxis to previous dose or vaccine component | Mild illness (cold, mild fever), Breastfeeding, Premature birth, Stable chronic disease |
| ALL Live Vaccines (BCG, OPV, MMR, Varicella, Yellow Fever) | Pregnancy, Severe immunodeficiency (HIV symptomatic, chemotherapy, high-dose steroids) | HIV-exposed but asymptomatic infant (BCG & OPV STILL given), Mild illness |
| DPT / Pertussis-containing | Encephalopathy within 7 days of previous DPT dose | Fever after previous dose (not contraindication), Family history of seizures, Stable neurological condition |
| MMR | Severe egg allergy (risk of anaphylaxis), Pregnancy, Immunocompromised | Mild egg allergy (MMR safe in most), Family history of autism (NO scientific basis) |
| Yellow Fever | Infants <6 months, Pregnancy, Immunocompromised, Thymus disease, Severe egg allergy | Breastfeeding (YF can be given), HIV-positive with CD4 >200 |
| Influenza (egg-based) | Anaphylaxis to eggs (not just allergy) | Mild egg allergy (can give with monitoring); egg-free alternatives available |
👩⚕️ Nursing Responsibilities in Immunisation
📋
Pre-Vaccination Assessment
- Check immunisation history and due vaccines
- Assess for contraindications (current illness, allergy history, immunocompromised)
- Take consent from parent/guardian
- Check VVM on vaccine vials before use
- Verify vaccine not expired, proper storage maintained
- Weigh child — dose depends on weight (some vaccines)
- Check 5 Rights of administration: Right vaccine, Right dose, Right route, Right site, Right patient
💉
Vaccine Preparation & Administration
- Use proper aseptic technique throughout
- Reconstitute freeze-dried vaccines (BCG, MMR, Varicella) just before use
- BCG: strictly INTRADERMAL (10–15°) — LEFT arm; wheal must form
- OPV: 2 drops orally; do NOT touch dropper to mouth
- IM vaccines: anterolateral thigh (<2 yrs), deltoid (>2 yrs)
- Never recap needles; dispose in puncture-proof sharps container
- Multiple injections: different sites/limbs; do not mix in same syringe
⏱️
Post-Vaccination Monitoring
- Observe child/patient for 30 minutes after vaccination — anaphylaxis watch
- Keep emergency kit ready: Adrenaline, Antihistamine, IV fluids, O₂
- Advise paracetamol for mild fever/pain at site
- Explain normal reactions: BCG scar, mild fever, soreness at site
- Advise when to return to hospital: high fever, convulsions, anaphylaxis signs
- Record in immunisation card & register immediately
- Check refrigerator temperature twice daily (morning & evening) — record in log
- Check VVM on each vial before use
- Open multi-dose vials last to prevent wastage
- Discard opened vials at end of session (BCG, MMR within 4 hours)
- Check shake test if freeze damage suspected
- Never put vaccines in freezer compartment of domestic fridge
- Report cold chain breaks immediately
📚
Parent/Community Education
- Importance of completing the vaccination schedule
- Common, expected side effects — fever, soreness
- BCG scar is normal and expected
- Debunk myths: vaccines do NOT cause autism, infertility, or other false claims
- Bring immunisation card to every visit
- Missed vaccines can be given later (no need to restart)
- Vaccines free of cost under UIP India
📝
Documentation & Reporting
- Record in child's immunisation card (MCP card — Mother & Child Protection card)
- Enter in facility immunisation register
- Report any AEFI on AEFI reporting form within 24–48 hours
- Maintain vaccine stock register — IN and OUT records
- Calculate dropout rates and immunisation coverage
- Report adverse events to district immunisation officer
Comments
Post a Comment